Consider the following statements regarding CAR-T cell therapy, its manufacturing process, and characteristic adverse events:

Statements

1. In CAR-T cell therapy, T cells are extracted from the patient, genetically re-engineered to target aberrant immune cells, and then reinfused into the same patient — making it an autologous, personalised immunotherapy.
2. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are well-recognised adverse events associated with CAR-T cell therapy, with ICANS manifesting as a neurological complication.
3. A compressed CAR-T manufacturing process — which shortens cell production time significantly compared with the conventional protocol — has been associated with infusion of cells in a more mature, fully differentiated state, reducing the risk of hyperinflammatory responses.